Benzinga

Benzinga

Benzinga

jueves, agosto 27

Spyre Therapeutics Inc

SYRENASDAQ
Trade with Public
Trade with Public
$93.61
0.010.01%
al cierre: Aug 27, 5:00 PM EST
$91.50
-2.11-2.26%
After hour: 4:16 PM EST
PRO
¿Por qué se mueve?:Spyre Therapeutics shares are trading lower after the company announced top...
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Spyre Therapeutics Financials

Spyre Therapeutics (SYRE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.73) by 50.68 percent. This is a 26.53 percent increase over losses of $(0.49) per share
Benzinga Newsdesk

PRO
Spyre Therapeutics Q1 EPS $(0.74) Misses $(0.68) Estimate

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.68) by 8.82 percent. This is a 23.33 percent decrease over losses of $(0.60) per share
Benzinga Newsdesk

PRO
Spyre Therapeutics Expects To Report That It Had ~$741M Of Cash, Cash Equivalents And Marketable Securities As Of March 31, 2026; Suspends And Terminates ATM Prospectus For At-The-market Offering Effective April 13, 2026

  Item 2.02    Results of Operations and Financial Condition.On April 13, 2026, Spyre Therapeutics, Inc. (the "Company") announced that while the Company has not finalized its full financial
Benzinga Newsdesk

Earnings Summary: Spyre Therapeutics Q4

Benzinga Insights

PRO
Spyre Therapeutics Q4 EPS $(0.70) Beats $(0.79) Estimate

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.79) by 10.83 percent. This is a 13.58 percent increase over losses of $(0.81) per share
Benzinga Newsdesk

PRO
Spyre Therapeutics Q3 EPS $(0.15) Beats $(0.74) Estimate

Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved